FDA Clocks Patent Time for LIMFLOW Medical Gadget
Published Date: 2/26/2026
Notice
Summary
The FDA has officially set the review period for the LIMFLOW SYSTEM, a medical device, so its patent can be extended. This affects the company behind LIMFLOW and anyone interested in patent timing or challenges. If you think the dates are wrong or the company wasn’t careful during review, you can speak up by April 27 or August 25, 2026.
Analyzed Economic Effects
2 provisions identified: 1 benefits, 0 costs, 1 mixed.
FDA Sets LIMFLOW Review Period
The FDA determined the regulatory review period for the LIMFLOW SYSTEM is 2,337 days in total: 2,022 days in the testing phase and 315 days in the approval phase. Key dates used were April 20, 2017 (investigational device exemption effective), November 1, 2022 (PMA submission), and September 11, 2023 (PMA approval); the applicant seeks either 1,033 or 1,327 days of patent term extension and the USPTO will apply statutory limits when calculating the actual extension.
Deadlines To Challenge Dates
People who think the dates are wrong may ask FDA for a redetermination by April 27, 2026, and anyone who believes the applicant did not act with due diligence may petition FDA by August 25, 2026. Petitions must follow the rules in 21 CFR 60.24 and 60.30 and be filed and served in the required manner (see Docket Nos. FDA-2024-E-3555; FDA-2024-E-3564; FDA-2024-E-3565).
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-10321 — Vaccines and Related Biological Products Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-Safety and Effectiveness of MFLUSIVA (Influenza Vaccine, mRNA) Manufactured by Moderna TX Inc.
The FDA is holding a public meeting on June 18, 2026, to talk about the safety and effectiveness of MFLUSIVA, a new flu vaccine made by Moderna. Anyone can watch online and share their thoughts before June 17. This is a big deal for people who get flu shots and could affect how this vaccine is used and approved.
2026-10295 — M11 Clinical Electronic Structured Harmonised Protocol (CeSHarP); International Council for Harmonisation; Guidance for Industry; Availability
The FDA just released a new, easy-to-use digital guide called M11 CeSHarP to help everyone involved in clinical trials share and review study plans faster and clearer. This affects drug companies, researchers, and regulators worldwide by setting a global standard for how trial info is written and shared electronically. The new rules kick in now, aiming to save time and reduce confusion, with no direct cost but big efficiency gains.
2026-10277 — Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability
The FDA just released new draft guides to help drug makers design studies proving their generic drugs work like the originals. If you’re in the drug business, now’s your chance to share feedback by July 21, 2026, before these guides become final. These updates aim to speed up drug approvals, potentially saving time and money for companies and patients alike!
2026-10284 — Protein Efficiency Ratio Rat Bioassay Studies To Demonstrate That a New Infant Formula Supports the Quality Factor of Sufficient Biological Quality of Protein; Guidance for Industry; Availability
The FDA just released new guidance to help baby formula makers prove their products have good-quality protein using special rat studies. This update affects formula manufacturers and labs, making it easier and clearer to show their formulas meet nutrition standards. The guidance is effective now, helping companies avoid costly mistakes and speed up getting new formulas to market.
2026-10268 — Notice of Decision Not To Designate Hepatitis Delta Virus Diseases as an Addition to the Current List of Tropical Diseases in the Federal Food, Drug, and Cosmetic Act
The FDA decided not to add Hepatitis Delta Virus (HDV) to the list of tropical diseases because it doesn’t fully meet the rules about market size and who it affects. This means drug makers won’t get special priority review vouchers for HDV treatments right now. People working on HDV drugs should keep an eye out for future updates but won’t see changes or new incentives immediately.
2026-10190 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Patent Term Restoration; Due Diligence Petitions; Filing, Format, and Content of Petitions
The FDA is updating how companies ask for extra patent time when their new drugs or devices take a while to get approved. This affects drug and medical device makers who want to protect their inventions longer. Comments on these changes are open until June 22, 2026, and the update aims to keep the process clear without adding extra costs or delays.
Previous / Next Documents
Previous: 2026-03854 — Notice and Request for Comment; Proposal for a New United Nations Global Technical Regulation on Automated Driving Systems (ADS)
The U.S. government wants your thoughts on a new global rule for self-driving cars to make sure they’re safe and work well. This affects car makers, tech companies, and anyone interested in automated driving. You’ve got until March 10, 2026, to share your ideas—no extra costs, just your voice helping shape the future of driving!
Next: 2026-03857 — Agency Information Collection Activities; Proposed Collection; Comment Request; Investigational Device Exemptions Reports and Records
The FDA is asking for public feedback on their plan to keep collecting info about investigational medical devices—those being tested for safety and effectiveness. This affects companies and researchers working on new medical devices, with no new costs or big changes, just a routine paperwork update. Comments are open until March 30, 2026, so now’s the time to speak up!